New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 2, 2012
14:15 EDTISRG, JNJ
theflyonthewall.com: da Vinci reimbursement set for April in Japan, says Collins Stewart
Collins Stewart confirmed with Intuitive Surgical (ISRG) management that the Japanese Ministry of Health indicated da Vinci prostatectomy is scheduled to be reimbursed beginning in April. The firm expects Intuitive Surgical, along with its Japanese partner Johnson and Johnson (JNJ), to pursue reimbursement for additional procedures. Collins Stewart says it is now more confident in Intuitive Surgical's long-term growth story and keeps a Buy rating on the stock. Note Lazard Capital said this morning in a note to investors that Japan is moving towards complete da Vinci prostatectomy reimbursement. :theflyonthewall.com



News For ISRG;JNJ From The Last 14 Days
Check below for free stories on ISRG;JNJ the last two weeks.
There are 13 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
May 25, 2012
11:13 EDTJNJ
theflyonthewall.com: Chairman: Elan may get offer if Alzheimer drug data positive, Reuters says
Elan's (ELN) chairman Bob Ingram said yesterday it was possible that the company could receive a takeover offer if data on an bapineuzumab, an experimental Alzheimer's drug it has a 25% economic interest in, is positive, reported Reuters. "If an offer comes in we can't ignore it, but it is not our strategy to sell the company," Ingram says. The drug is being developed by Pfizer (PFE) and Johnson and Johnson (JNJ), Reuters noted. Reference Link :theflyonthewall.com
09:31 EDTJNJ
theflyonthewall.com: Johnson & Johnson to host conference call

Subscribe for More Information
:theflyonthewall.com

May 24, 2012
07:13 EDTJNJ
theflyonthewall.com: J&J's Xarelto likely delayed 3-12 months, not dead, says Leerink
Leerink believes the FDA panel vote against approval of Johnson & Johnson's (JNJ) and Bayer's (BAYRY) Xarelto for the prevention of CV events in patients with a recent acute coronary syndrome will likely delay approval by 3-12 months, not kill the drug for this indication. The firm believes Bristol-Myers' (BMY) and Pfizer's (PFE) Eliquis could benefit slightly from a Xarelto delay. :theflyonthewall.com
06:50 EDTJNJ
theflyonthewall.com: Johnson & Johnson Group option implied volatility low

Subscribe for More Information
:theflyonthewall.com
06:06 EDTJNJ
theflyonthewall.com: Johnson & Johnson unit confirms FDA panel vote against XARELTO

Subscribe for More Information
:theflyonthewall.com
06:05 EDTJNJ
theflyonthewall.com: FDA panel rejects Johnson & Johnson's Xarelto 6-4, AP reports

Subscribe for More Information
:theflyonthewall.com

May 23, 2012
16:21 EDTJNJ
theflyonthewall.com: FDA panel rejects Johnson & Johnson's XARELTO 6-4, Bloomberg reports

Subscribe for More Information
:theflyonthewall.com
07:10 EDTJNJ
theflyonthewall.com: FTC, Senate probing blocking of generic drug companies, Washington Post says
The Federal Trade Commission and the U.S. Senate are investigating whether pharmaceutical companies are using a loophole to prevent generic drug makers from obtaining samples of brand name drugs, according to The Washington Post. The FDA requires generic drug makers to test a sample of brand name versions in order to get a generic drug approved, the newspaper notes. Reference Link :theflyonthewall.com

May 21, 2012
14:38 EDTJNJ
theflyonthewall.com: Janssen presents data from Phase 3 study of anti-TNF Simponi
Janssen Research & Development said that new study findings show that subcutaneous induction regimens of the anti-tumor necrosis factor-alpha therapy Simponi induced clinical response in a majority of patients with moderately to severely active ulcerative colitis who had previously failed or were intolerant to conventional agents. Investigators presented data from the Janssen-sponsored Phase 3 study at Digestive Disease Week during a late breaker session and reported that more than 50% of patients in each of two Simponi dosing groups achieved clinical response at week 6, the primary endpoint of the study, which was significantly more than those in clinical response after receiving placebo. Treatment with Simponi also resulted in significant induction of clinical remission and mucosal healing and improvement in health-related quality of life measures at week 6 compared with placebo, Janssen said. :theflyonthewall.com
09:43 EDTJNJ
theflyonthewall.com: Johnson & Johnson management to meet with JPMorgan
Meeting to be held in Boston on May 24 hosted by JP Morgan. :theflyonthewall.com

May 18, 2012
08:14 EDTISRG
theflyonthewall.com: BofA/Merrill's medtech analyst research team holds a conference call

Subscribe for More Information
:theflyonthewall.com

May 15, 2012
09:37 EDTJNJ
theflyonthewall.com: Summer Street's biotech research team hosts a luncheon meeting

Subscribe for More Information
:theflyonthewall.com

May 14, 2012
06:42 EDTJNJ
theflyonthewall.com: Johnson & Johnson option implied volatility low

Subscribe for More Information
:theflyonthewall.com